[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Armed Forces Hospital, Pakistan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100589725","phase-4-azithromycin-for-preventing-maternal-and-neonatal-infections-during-labor-100589725",false,"NCT06958146","Azithromycin for Preventing Maternal and Neonatal Infections During Labor.","Impact of Single Dose Azithromycin During Labor on Maternal and Neonatal Infections","Inclusion Criteria:\n\n* pregnant ladies with no risk factors for sepsis who go into spontaneous labor or induced labor\n\nExclusion Criteria:\n\n* pregnant with risk factors for sepsis like maternal fever , raised WBC count, chorioamnionitis, or having. history of any adverse even with macrolides","FEMALE","18 Years","45 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","In this study, we want to see the role of the antibiotic, azithromycin, in preventing maternal and neonatal infections, if the drug is given intrapartum to the mother",[27,28],"Maternal and Neonatal Sepsis","Intrapartum Antibiotics","NOT_YET_RECRUITING","2025-04-28",{"date":32,"type":33},"2025-05-06","ACTUAL",{"date":35,"type":21},"2025-05-01",{"date":37,"type":21},"2025-08-31",{"name":39,"class":40},"Armed Forces Hospital, Pakistan","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100556244","phase-1-role-of-citicoline-in-treatment-of-neonates-with-hypoxic-ischemic-encephalopathy-100556244","NCT06522581","Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy","Inclusion Criteria:\n\n1. all indoor newborn babies with HIE II and III\n2. who have not received therapeutic hypothermia\n\nExclusion Criteria:\n\n1. grade I HIE\n2. Babies on TH\n3. babies whose parents do not give consent for inclusion in study\n4. babies with major congential malformations -","ALL","1 Day","30 Days",{"count":51,"type":21},200,[53],"PHASE1","Hypoxic ischemic encephalopathy is an acute or subacute brain injury, due to asphyxia in neonates, leading to mortality and long-term morbidity. Its prevalence varies across regions, with developed countries reporting rates of 1.5 per 1000 live births, while developing nations experience a wider range from 2.3 to 26.5 per 1000 live births.\n\nInfants afflicted with moderate HIE face a 10% risk of mortality, with surviving individuals encountering a 30% chance of developing disabilities. The prognosis is graver for severe HIE, with a mortality risk of 60%, and nearly all survivors experiencing some form of disability.",[56],"Hypoxic Ischemic Encephalopathy of Newborn","RECRUITING","2024-08-12",{"date":60,"type":33},"2024-08-14",{"date":62,"type":33},"2024-01-01",{"date":64,"type":21},"2025-01-01",{"name":39,"class":40},1,""]